Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA7 | P43166 | 5/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060893 | 0.85 | CA1 (0.42) | LMNACA1CA2CA9CA12 | |
| SCHEMBL5041575 | 0.84 | LMNA (0.48) | LMNACA1CA2CA9CA12 | |
| SCHEMBL19683166 | 0.84 | CA1 (0.43) | CA1CA2CA9CA12CA7 | |
| SCHEMBL21157746 | 0.83 | CA1 (0.49) | LMNACA1CA2CA9CA12 | |
| SCHEMBL13527224 | 0.83 | CA1 (0.41) | LMNACA1CA2CA9CA12 | |
| SCHEMBL9969521 | 0.81 | CYP2D6 (0.39) | CA1CA2CA9CA12CA7 | |
| SCHEMBL13526959 | 0.81 | CYP2D6 (0.39) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16788802 | 0.81 | CYP2D6 (0.39) | CA1CA2CA9CA12CA7 | |
| SCHEMBL29813063 | 0.78 | LMNA (0.56) | LMNACA1CA2CA9CA12 | |
| SCHEMBL25901847 | 0.78 | CA1 (0.42) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | LMNA 2857/4885CA1 3502/4885CA2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.